For example,
Immunotherapy: cancer better treated morning:
Immunotherapy. Moreover, chemotherapy
Cancer is better treated in the morning than in the evening – Immunotherapy: cancer better treated morning
Studies suggest that the time at which treatment is administered plays a role. In addition, A Bernese oncologist wants to test this hypothesis, but does not find funding.
Studies suggest that the hour at which a patient with cancer receives his treatment is not trivial.
Getty Images
- A Chinese study reveals that the effectiveness of advanced lung cancer is much higher if administered before 3 p.m.
- Patients treated in the morning immunotherapy: cancer better treated morning survive significantly longer depending on the data.
- Bernese oncologist Berna Özdemir wishes to conduct a similar study in Switzerland.
- The lack of public funding is currently slows down independent clinical research.
Are chemotherapy and immunotherapy more effective in the morning? Meanwhile, In recent years, studies suggest that the hour at which a patient with cancer receives his treatment is not trivial.
In May. Furthermore, a Chinese team caused a sensation at the annual meeting of the American Society of Clinical Oncology (ASCO, American clinical oncology company). Furthermore, She presented the randomized first On this issue of chronotherapy – namely the study which takes into account. In addition, the natural biological rhythms of the body to optimize the effectiveness of care.
Two hundred. Moreover, ten people with advanced lung cancer have been encompassed in immunotherapy: cancer better treated morning this research, the results of which show that if the first four chemotherapy and immunotherapy treatments (both are combined for the disease studied) are provided before 3 p.m., the results are much better.
At this point, you will find additional external content. Therefore, If you accept that cookies are placed by external suppliers. Meanwhile, that personal data are transmitted to them, you must allow all cookies and directly display external content.
In individuals treated in the evening, cancer reappears after 6.5 months (median figures), against 13.2 months for the morning team. In addition, the general survival in the first group is 17.8 months, while it is not determined after 18 months in the second.
“According to Chinese experts. Nevertheless, it is likely that these morning patients live twice as immunotherapy: cancer better treated morning long as the others, which is enormous,” said Berna Özdemir, an oncologist at the island hospital in Berne. For example, Despite the doubts of certain colleagues, the doctor believes that the results of this “well -conducted” study are “plausible”.
It is only if theimmunotherapy has more than demonstrated its effectiveness in recent years. it is difficult to understand why some patients respond better than others. Would chronotherapy provide part of the answer? According to Berna Özdemir, Chinese conclusions are based in any case on a biological logic.
The cells have a clock form, which defines when they divide or send certain signals. Therefore, we can imagine that our immune answers change over the day. Experiments on animals. men have also shown that the reaction to certain vaccines (especially against the covid Or against pneumococci) is higher immunotherapy: cancer better treated morning if administered during the period of the day when the guinea pig is active.
Immunotherapy: cancer better treated morning
Hopeful study in Bern
If the subject interests Berna Özdemir. it is also because it is an inexpensive and non -toxic solution to improve treatments. She would like to do a search on the subject in turn. and confirm the interest in changing the planning of treatments before revolutionizing the daily lives of hospitals and patients.
According to her. it should be confirmed in particular that no variable hidden false the results, and that there are no differences between the Chinese and European populations. She also notes that the limit set at 3 pm is “arbitrary”. “Other studies have placed it at 1 p.m. or 4:30 p.m. on this point. differences between individuals, linked in particular to immunotherapy: cancer better treated morning their age, their lifestyle or their gender, deserve to be invested.”
L’Oncologue Berna Özdemir.
DR
Berna Özdemir designed her study protocol two years ago. It would be a question of carrying out a test with some 200 patients with melanoma, lung or kidney cancer. But public funding is rare and it does not find the necessary funds.
“It’s a shame. Lack of money puts immunotherapy: cancer better treated morning clinical research in danger. when they could improve the survival and daily life of patients, regrets the oncologist. Such tests are possible in other countries. If we want to remain innovative, we must be able to follow. ”
Lack of funds for chronotherapy studies
Vincent Gruntz, CEO of the Swiss Cancer Institute (SCI), knows this problem too well. Its organization. which brings together university hospitals and their researchers in oncology and which is notably supported by the Confederation, aims precisely to support research based on the questions that doctors ask themselves in their daily practice.
Vincent Gruntz, CEO du Swiss Cancer Institute (SCI).
DR
“The pharmaceutical industry focuses on innovation,” sums up the Basel. But clinical studies without commercial interest also make it possible to progress. And this at significantly lower costs since it is not a question of introducing new substances on the market. but rather of modifying the dosage of a drug or to extend its indication to other pathologies. ”
Examples? The use of aspirin or magnesium could increase the efficiency of certain treatments. But we fall back on the matter of money. “The Confederation has reduced its support. has become particularly difficult for independent and non -profit clinical research to obtain funds. In an international comparison, this sector is underfunded in immunotherapy: cancer better treated morning Switzerland, in particular in comparison with basic research, ”deplores Vincent Gruntz.
Within the SCI, more than fifty protocols, including that of Berna Özdemir, await funding. The Bernese. precisely, concludes: “The risk is to have to put projects in the trash that have requested a lot of energy, and to discourage future commitments.”
Did you find an error? Please report it to us.
Further reading: Salt moves his Renens headquarters in Prilly – Valuing, Switzerland ends up giving in against Spain – RTS.CH – “Deaf dialogue” in plastic discussions in Geneva – The Swiss scholarship remains in the red before Jackson Hole – Cantons of Geneva and Vaud: “Wooden mouth” and “cold shower”.
